In 2008 following examination by autopsy of four people from the trial, Tuszynski noted that each subject exhibited a clear increase in cholinergic cell growth in response to NGF, and concluded that “additional clinical trials of NGF for Alzheimer’s disease are warranted” [176]. This evidence concerns the gene NGF and early-onset autosomal dominant Alzheimer disease.